SCHEMBL6540392

SCHEMBL6540392

COc1cccc(Sc2ccc(C=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
CYP2A6 P11509 1/20 0.52
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
CYP1A2 P05177 2/20 0.49
CYP1A1 P04798 1/20 0.49
CYP1B1 Q16678 1/20 0.49
PTGIR P43119 1/20 0.46
TERT O14746 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RELA Q04206 1/20 0.44
EDNRA P25101 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4800339 0.89 NPC1 (0.50) ALDH1A1CYP2A6MTNR1AMTNR1BCYP1A2
SCHEMBL10709610 0.86 MTNR1A (0.57) ALDH1A1MTNR1AMTNR1BCYP1A2CYP1A1
SCHEMBL6255853 0.84 NPC1 (0.52) ALDH1A1CYP2A6MTNR1AMTNR1BCYP1A2
SCHEMBL9770219 0.83 HTR2C (0.55) ALDH1A1MTNR1AMTNR1BCYP1A2CYP1A1
SCHEMBL4615766 0.83 ALDH1A1 (0.76) ALDH1A1CYP2A6CYP1A2CYP1A1CYP1B1
SCHEMBL31425668 0.82 ACHE (0.54) ALDH1A1MTNR1AMTNR1BPTGIRCYP3A4
SCHEMBL3164341 0.82 ACHE (0.54) ALDH1A1MTNR1AMTNR1BPTGIRCYP3A4
SCHEMBL2706311 0.82 CYP3A4 (0.47) ALDH1A1MTNR1AMTNR1BTERTSIRT2
SCHEMBL13163776 0.81 EDNRA (0.54) ALDH1A1MTNR1AMTNR1BCYP1A2PTGIR
SCHEMBL24433577 0.80 ACHE (0.52) ALDH1A1MTNR1AMTNR1BPTGIRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016019588-A1 OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE THE BROAD INSTITUTE, INC. (US) 2016-02-11 WO disclosed
WO-2016019588-A1 OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE THE BROAD INSTITUTE, INC. (US) 2016-02-11 WO disclosed
US-20040138462-A1 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2004-07-15 US disclosed
US-20040106653-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-03 US disclosed
WO-2004045610-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD (JP) 2004-06-03 WO disclosed
EP-1389185-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-02-18 EP disclosed
WO-2002094770-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138462-A1 Aminoalcohol derivatives BPHL, FANCD2, HRH2 ALDH1A1 188/4885CYP2A6 2568/4885MTNR1A 245/4885
US-20040106653-A1 Aminoalcohol derivatives FANCD2, FANCI, HRH2 ALDH1A1 168/4885CYP2A6 2576/4885MTNR1A 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.